Sandy Huffaker for STAT

STAT+ | A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope

An exon-skipping drug delivered striking results, but the Duchenne muscular dystrophy field has been burned before and some fear history could repeat.

By Jason Mast

STAT+ | Everyone agrees AI scribes are increasing health care costs. No one agrees what to do about it

It's unclear how the health care industry will handle technology-driven inflation, especially in the face of political pressure to lower health care costs.

By Brittany Trang

STAT+ | 23andMe finds genetic changes appear to help predict response to GLP-1 drugs for weight loss

New research by the 23andMe Research Institute suggests genetic changes appear to help predict whether patients will lose substantial weight on GLP-1 drugs.

By Matthew Herper

Opinion: How sports betting is hooking some young men

Isaac Rose-Berman on the rise of sports gambling as public health threat — and what to do about it.

By Torie Bosch

STAT+ | Steve Ubl to step down as CEO of PhRMA

The powerful pharmaceutical industry lobbying group PhRMA has faced off with both Republicans and Democrats over efforts to rein in drug prices.

By John Wilkerson

Smart contact lens monitors eye pressure and delivers glaucoma drugs in early tests

Device monitors ocular pressure without need for electronics or a battery, and delivers pulses of glaucoma drug as needed. 

By Annalisa Merelli

David Ryder/Getty Images

Opinion: What American hospitals can learn from India about waste

When these medical students visited hospitals in India, they learned that medicine does not have to be so bad for the environment.

By Srinidhi Polkampally and Bhav Jain